Simvastatin as a neuroprotective treatment for Parkinson’s disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity by Hayward, C
 
Statistical Analysis Plan 
 
 
 
 
 
Simvastatin as a neuroprotective treatment for         
moderate Parkinson’s disease 
 
 
 
Simvastatin as a neuroprotective treatment for Parkinson’s disease:                 
a double-blind, randomised, placebo controlled futility study                             
in patients of moderate severity 
 
 
 
 
 
 
PD STAT SAP V2.1 24082020 Page 2 of 48 
 
 
CONTENTS 
Administrative Information .................................................................................................................... 4 
Abbreviations .......................................................................................................................................... 9 
1 Introduction .................................................................................................................................. 10 
1.1 Background and Rationale for the Trial ................................................................................ 10 
1.2 Purpose of statistical analysis plan ....................................................................................... 10 
2 Trial Objectives and Outcome Measures ...................................................................................... 10 
2.1 Primary Objective.................................................................................................................. 10 
2.1.1 Primary Outcome Measures ......................................................................................... 11 
2.2 Secondary Objectives ............................................................................................................ 11 
2.2.1 Secondary Outcome Measures ..................................................................................... 11 
2.3 Practically–Defined OFF State ............................................................................................... 12 
3 Trial Design .................................................................................................................................... 13 
3.1 General Design ...................................................................................................................... 13 
3.1.1 COVID-19 Adaptions ..................................................................................................... 13 
3.2 Blinding ................................................................................................................................. 13 
3.3 Analysis Populations ............................................................................................................. 13 
3.3.1 COVID-19 Analysis Populations ..................................................................................... 14 
3.4 Inclusion and Exclusion Criteria ............................................................................................ 14 
3.4.1 Inclusion Criteria ........................................................................................................... 14 
3.4.2 Exclusion Criteria ........................................................................................................... 14 
4 Statistical Principles ...................................................................................................................... 15 
4.1 Randomisation, Allocation Concealment and Stratification ................................................. 15 
4.2 Sample Size Calculation ........................................................................................................ 15 
4.3 Statistical Significance Levels ................................................................................................ 17 
4.4 Compliance and Protocol Violations ..................................................................................... 17 
4.4.1 Compliance to Allocated Treatment ............................................................................. 17 
4.4.2 Protocol Violation or Deviation ..................................................................................... 17 
4.5 Timing of Collection of Outcome Measures ......................................................................... 19 
4.6 Derived Variables .................................................................................................................. 19 
4.7 Interim Analysis ..................................................................................................................... 20 
4.8 Time points of Statistical Analysis ......................................................................................... 20 
4.9 Data Sources and Data Quality ............................................................................................. 20 
 
 
 
 
 
PD STAT SAP V2.1 24082020 Page 3 of 48 
 
 
4.10 Missing Data .......................................................................................................................... 21 
4.10.1 Missing Primary Outcome Data .................................................................................... 21 
4.10.2 Other Missing Data ....................................................................................................... 22 
4.10.3 Missing Data as a Consequence of COVID-19 ............................................................... 22 
5 Study Population ........................................................................................................................... 22 
5.1 Participants who discontinue, withdraw or are lost to follow-up ........................................ 23 
5.2 Baseline characteristics and demographics .......................................................................... 23 
6 Statistical Analyses ........................................................................................................................ 24 
6.1 General Considerations ......................................................................................................... 24 
6.2 Adjustments .......................................................................................................................... 24 
6.3 Statistical Software ............................................................................................................... 24 
6.4 Reporting Conventions ......................................................................................................... 25 
7 Analysis of the Primary Outcome ................................................................................................. 25 
7.1 Outcome Variable ................................................................................................................. 25 
7.2 Primary Analysis: Futility Analysis ......................................................................................... 25 
7.2.1 Interpretation of the results of the primary analysis .................................................... 25 
7.3 Sensitivity Analyses of the Primary Outcome ....................................................................... 27 
7.3.1 Non-Compliance Sensitivity Analysis ............................................................................ 27 
7.3.2 Location of Face-to-Face Visit Sensitivity Analysis ........................................................ 29 
7.3.3 COVID-19 Sensitivity Analysis ....................................................................................... 29 
7.4 Secondary Analyses of the Primary Outcome ....................................................................... 29 
7.4.1 Repeated Measure Model ............................................................................................ 29 
7.4.2 Disease-Modifying Analysis ........................................................................................... 30 
7.5 Superiority Analysis ............................................................................................................... 31 
8 Analysis of Secondary Outcomes .................................................................................................. 32 
8.1 Secondary Outcome Variables .............................................................................................. 32 
8.2 Secondary Outcomes Analysis .............................................................................................. 33 
8.2.1 COVID-19 Sensitivity Analyses of Secondary Outcomes ............................................... 34 
9 Safety Data .................................................................................................................................... 34 
10 References ................................................................................................................................ 36 
Appendix ............................................................................................................................................... 39 
A. Additional Information for Outcome Measures ....................................................................... 39 
B. Examples of Figures and Tables for Reporting Study Results ................................................... 42 
C. Superiority Analysis Correspondence ....................................................................................... 46 
 
 
 
 
 
PD STAT SAP V2.1 24082020 Page 4 of 48 
 
 
ADMINISTRATIVE INFORMATION 
Short Title of Trial Simvastatin as a neuroprotective treatment for moderate Parkinson’s 
disease 
Full Title of Trial Simvastatin as a neuroprotective treatment for Parkinson’s disease: 
a double-blind, randomised, placebo controlled futility study in 
patients of moderate severity 
Trial Registration 
Numbers 
EudraCT number: 2015-000148-40  
ISRCTN16108482 
REC Reference: 15/NE/0324  
Protocol Version  4.5 (2nd February 2019) 
SAP Version 2.1 (24th August 2020) 
SAP Revisions Revisions 15th July 2020 (Statisticians’ blinding maintained) 
Following final review of paper-based CRFs during the data cleaning 
process, a small proportion of participants from multiple sites were 
identified where the assessor had annotated the CRF to include 
separate left hand and right hand postural tremor scores (see section 
4.10.1 on missing an item from question 15 of the MDS-UPDRS part 
III). Prior to database lock, the trial database was updated to include 
these additional data. After discussion with the PD STAT Trial 
Management Group (13/07/2020), it was agreed that the calculation 
of the primary outcome should utilise all available data.  
Therefore, section 4.10.1 is updated as follows: 
For a small proportion of participants, the assessor manually 
annotated the case report forms and included postural tremor scores 
for the left and right hand. In these instances, the scores for both left 
and right hands will be used as part of the calculation of the primary 
outcome. However, if a participant only has one postural tremor score, 
the second postural tremor score will be treated as missing data (not 
at random).  
For a maximum of three missing items, imputation of the MDS-UPDRS 
part III total score will be undertaken according to the following 
equation…… 
…… For the purposes of pre-defined sensitivity analyses of the 
primary outcome (outlined in section 7.3), the requirement of no more 
than three missing items will be relaxed. 
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Following a detailed examination of the MDS-UPDRS part IV during 
final data cleaning, it was identified that for questions 1, 3 and 6 
assessors had not always completed the calculations required to 
determine the item score. After discussion with the Trial Management 
Group (13/07/2020), it was decided missing scores will be calculated 
by the trial statisticians after database export, if all the necessary data 
is available. 
Therefore Table 5 of Appendix A was amended to include: 
MDS-UPDRS 
part IV 
For questions 1, 3 and 6, the score is based on the 
percentage reported in part C of each question, 
which is calculated by dividing the number of hours 
stated in part B by the number of hours stated in 
part A and multiplying by 100. For each of 
questions 1, 3 and 6, the question score is then:  
 0 if part B = 0 
 1 if part C ≤ 25% 
 2 if part C is 26-50% 
 3 if part C is 51-75% 
 4 if part C > 75%. 
In instances where the ordinal score is missing but 
part C (the percentage) is available, the score will 
be determined based on the above thresholds of 
the reported part C. If the ordinal score and part C 
are missing but part A and B are available, part C 
(the percentage) will be calculated and the ordinal 
score determined by the above defined thresholds.  
 
Revisions 15th July 2020 (Statisticians’ blinding maintained) 
It was identified that Equation 4 and Equation 5 in section 7.4 were 
missing the participant random effect. This had now been included as 
the term 𝑈𝑖,𝑗 and the definition:  
 𝑈𝑖,𝑗~ 𝑁(0, 𝜎𝑢
2)  is the random effect for participant 𝑗 in cluster 𝑖, 
independent of 𝑍𝑖 
added to the list of definitions following Equation 4. 
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Revisions 27th July 2020 (Statisticians’ blinding maintained) 
In section 7.4.2 of the SAP v1.1 (15/07/2020), the disease-modifying 
model of MDS-UPDRS part III (OFF) total score observed at baseline, 
12, 24 and 26 months erroneously included an adjustment for the 
baseline MDS-UPDRS part III (OFF) total score. As part of the 
dependent variable, this should not also be included as an 
independent variable in the repeated measures or disease modifying 
models. Therefore, the text “which is instead adjusted for as a fixed 
effect within 𝜽”, has been deleted. 
Following a review of the Adverse Events (AE) data, it was identified 
that the information required to determine whether an IMP 
discontinuation was due to either an AE or SAE had not been 
obtained. Therefore, instead of reporting the number of withdrawals 
and discontinuations due to AEs, summary statistics of AEs of all 
participants who discontinue or withdraw will be reported and section 
9 has been updated to: 
The number and percentage of adverse events (AEs) will be reported 
by participant’s completion status (i.e. completed IMP, discontinued 
IMP and withdrew) and by treatment taken (i.e. placebo, 40mg only or 
80mg). 
Revision 7th August 2020 (Statisticians’ blinding maintained) 
At the time of finalising the SAP v1.1 (15/07/2020), it was assumed 
that all visits undertaken after the introduction of government social 
distancing measures on 23rd March 2020 would be conducted 
remotely. As remote visits had not been an option prior to the COVID-
19 lockdown, the presence of a remote visit was planned to be used 
as a proxy/indicator for an outcome measured during COVID-19 
lockdown. However, following data export, it became apparent that 
one participant visit was completed face-to-face shortly after this date, 
on 25th March 2020. As a result, it was necessary to implement the 
following revisions to clarify that all outcome collection visits 
completed after 23rd March 2020 will be considered to be “COVID-19 
affected” visits:  
Section 3.3.1 
The non-COVID-19 population will consist of participants whose 
data collection visits were completed on or prior to the 
introduction of government social distancing measures on 23rd 
March 2020. 
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Section 7.4.2.1 
…… will include an indicator variable that identifies whether the 
visit was completed during COVID-19 lockdown. The estimated 
coefficient and associated 95% confidence interval of the COVID-
19 indicator variable will be used to understand the effect of 
COVID-19 on the disease-modifying analysis. 
Section 8.2.1 
…… provided valid 24-month data during COVID-19 lockdown 
will be undertaken. Specifically, the analyses of each of the 
secondary outcomes will be repeated excluding participants who 
provided 24-month outcome data during COVID-19 lockdown 
when social distancing measures were in place (i.e. the non-
COVID-19 population). 
 
Revision 24th August 2020 (Group allocations revealed) 
At the TMG meeting on 21st August 2020, it was discussed that 
missing items within the ACE-III were currently being set to zero. This 
could potentially lead to miss-assigning a participant a low ACE-III 
total score due to physical impairment rather than cognitive 
impairment. The decision was made to set the total ACE-III total score 
to missing for any participant missing one or more ACE-III items. 
Therefore, Table 5 in Appendix A was amended to: 
ACE-III Participants with any missing items set total score to 
missing (approach 3, Lees et.al 41) 
 
 
SAP Clarifications (i) To maximise all available data, the disease-modifying analysis 
will use the compliance definition exactly as specified in section 
4.4.2(i), such that the ±2-week visit window only applies to the 
24-month follow-up visit. 
 
(ii) In section 6.2 the adjustment for the modified Hoehn and Yahr 
score will be conducted according to the cut-off used to stratify 
the randomisation procedure (i.e. ≤2.0 versus 2.5-3.0). 
 
(iii) For all 24-month group comparisons in which the model adjusts 
only for baseline (as per section 6.2), random effects for centre 
will not be included. 
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(iv) Analysis of the BTT in section 8 should only use the first 
measurement of frequency of taps in 30 seconds for each hand 
at each visit, as an error within the BTT website resulted in 
multiple uploads of the same data or the participants repeating 
the tests as the website indicated the initial test had not been 
successful. 
 
(v) The pre-specified COVID-19 sensitivity analyses of the 
secondary outcomes, as outlined in section 8.2.1, pertain only to 
the analysis models in which the 24-months outcomes are treated 
as the dependent variables (i.e. there is no planned COVID-19 
sensitivity analyses of the repeated measures models). Given no 
data collection visits at baseline or 12-month follow-up were 
undertaken during the COVID-19 lockdown period, COVID-19 
sensitivity analyses of the repeated measures models are not 
considered necessary.  
 
(vi) Cholesterol levels that exceed 10mmol/L will be excluded from 
analyses, as these are considered clinically spurious values. 
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1 INTRODUCTION 
1.1 BACKGROUND AND RATIONALE FOR THE TRIAL 
The full background and rationale for the trial can be found in the PD STAT protocol1. In 
summary, Parkinson’s disease (PD) is a progressive neurodegenerative condition affecting 
more than 127,000 people in the UK, with a further 10,000 individuals being diagnosed with 
the condition each year. No drug has been shown to slow or reverse the neurodegenerative 
process of PD. All currently licensed therapies act as symptom-relieving agents but have a 
limited lifespan of effectiveness because of continued neuronal loss. Epidemiological studies 
support a potential neuroprotective role for statins in PD, as statin use has been associated 
with a lower incidence rate of PD2 3. Various studies have suggested an association between 
the cholesterol lowering drug, Simvastatin, and a reduction in the rate of brain atrophy in 
secondary progressive multiple sclerosis4.  
The purpose of this futility study is to determine whether Simvastatin, a widely used 
cholesterol-lowering drug (statin), has potential to reduce the rate of neurodegenerative 
decline in patients with PD. The study is part of the Linked Clinical Trials initiative coordinated 
by The Cure Parkinson’s Trust5. 
1.2 PURPOSE OF STATISTICAL ANALYSIS PLAN 
The study protocol includes an outline of the statistical methods to be employed in the analysis 
of the trial data. The purpose of the Statistical Analysis Plan (SAP) is to provide full details of 
the planned statistical methods to be used in the primary report of the trial results. 
The SAP has been drafted following published SAP Guidelines6, also taking cognisance of the 
CONSORT for  parallel group trials7, the extension for reporting patient-reported outcomes8 
and Harms9. However, it is worth noting that, as this is a futility trial, there will be some 
differences in the analysis of the outcome measures and presentation of the results compared 
to a typical definitive randomised trial. 
The electromagnetic sensor measurement and genetic sub-studies will be analysed 
separately by collaborators on the PD-STAT project. The statistical analyses outlined in this 
SAP do not pertain to data gathered from either of these sub-studies. 
2 TRIAL OBJECTIVES AND OUTCOME MEASURES 
The main objective of this trial was to determine the futility of Simvastatin in reducing 
neurodegenerative decline in patients with PD. The outcome measures will be recorded at 
baseline, 12, 24 and 26 months. 
2.1 PRIMARY OBJECTIVE 
To determine whether Simvastatin is clearly ineffective (futile) in preventing the clinical decline 
of PD, as measured by the Movement Disorder Society Unified Parkinson’s Disease Rating 
Scale (MDS-UPDRS)10 motor score. 
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2.1.1 Primary Outcome Measures 
The primary outcome is change in MDS-UPDRS part III motor subscale score in the OFF state 
over 24 months. MDS-UPDRS part III score consists of 33 items, where each item is scored 
between 0 (normal) and 4 (severe). The OFF state is defined as the absence of the 
participant’s regular PD medication so that the severity of the underlying disease is evident; 
more details can be found in section 2.3. 
2.2 SECONDARY OBJECTIVES 
The secondary objectives are to: 
i. Confirm the safety and tolerability of Simvastatin in patients with PD.  
ii. Distinguish symptomatic effects of Simvastatin from disease modifying effects.  
iii. Evaluate the impact of Simvastatin on: 
a) activities of daily living (ADL)  
b) timed motor tests 
c) cognitive ability 
d) mood 
e) behaviour 
f) non-motor symptoms  
g) quality of life. 
2.2.1 Secondary Outcome Measures 
The secondary outcome measures collected at baseline, 12, 24 and 26 months are: 
i. MDS-UPDRS total score in the practically defined ON state – the total score consists of 
65 items, where each item is scored between 0 (normal) and 4 (severe).  
 
ii. MDS-UPDRS part II subscale score in the practically defined ON state – the part II score 
consist of 13 items, where each item is scored between 0 (normal) and 4 (severe).  
 
iii. Timed motor tests:  
 
a) brain tap test11 in the OFF state, where the measurement used is the number of 
key taps in 30 seconds, 
 
b) 10 metre walk test (10MWT)12 in the OFF state, which will consist of two 
components: number of 10MWTs the participant was able to complete out of three, 
and the mean time taken to successfully complete 10MWT.  
 
iv. Montgomery and Asberg Depression Rating Scale (MADRS)13 14 – a 10-item physician 
rated depression severity scale where each item is scored from 0 (best) to 6 (worst). 
 
v. Addenbrooke’s Cognitive Examination-III (ACE-III)15 – total score which includes five 
subdomains: attention (score: 0-18), memory (score: 0-26), fluency (score: 0-14), 
language (score: 0-26) and visual spatial (score: 0-16). 
 
vi. Non-Motor Symptom scale (NMSS)16 – total score which comprises of 30 item rater-
based instrument, specifically designed for the comprehensive assessment of non-
motor symptoms in patients with PD. It contains nine dimensions: cardiovascular (2 
items), sleep/fatigue (4 items), mood/cognition (6 items), perceptual problems (3 items), 
attention/memory (3 items), gastrointestinal (3 items), urinary (3 items), sexual function 
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(2 items) and miscellaneous (4 items). Each item is scored for severity (0-3) and 
frequency (0-4). 
 
vii. Parkinson’s disease Questionnaire (PDQ-39)17 total score – this questionnaire 
assesses how often people affected by Parkinson's experience difficulties. It consists of 
39 items across eight discrete dimensions: mobility (10 items), activities of daily living (6 
items), emotional well-being (6 items), stigma (4 items), social support (3 items), 
cognitions (4 items), communications (3 items) and bodily discomfort (3 items). Each 
item is scored between 0 (never) and 4 (always).  
 
viii. Levodopa-equivalent dose (LED) – this measure allows for comparison of different types 
of PD medication by calculating the equivalent dose in Levodopa. 
 
ix. Cholesterol levels – this will include measurements of total, HDL, total/HDL ratio 
cholesterol levels. 
 
x. King’s PD pain scale (KPPS)18 total score - a PD specific pain score consisting of 14 
items within seven domains: musculoskeletal pain (1 item), chronic pain (2 items), 
fluctuation related pain (3 items), nocturnal pain (2 items), orofacial pain (3 items), 
discoloration and Oedema/swelling (2 items) and radicular pain (1 item). Each item is 
scored for severity (0-3) and frequency (0-4). 
 
xi. EuroQoL 5D-5L health status questionnaire (EQ-5D-5L)19. 
At 24 months incidence of diabetes mellitus, determined by a glycated haemoglobin (HbA1c) 
level ≥ 6.5% (48mmol/mol) (WHO 2011), will also be recorded.  
Every two months the safety and tolerability data will be gathered, using adverse events 
reporting, via telephone contacts (2 weeks, 2, 4, 8, 10, 14, 16, 20 and 22 months post-
baseline) or during a follow-up visit (baseline and at 1, 6, 12, 24 and 26 months post-baseline). 
In addition, the number of capsules returned will be recorded every 6 months, in order to aid 
the determination of tolerability and compliance. 
2.3 PRACTICALLY–DEFINED OFF STATE  
The MDS-UPDRS part III and the timed motor tests at baseline, 12, 24 and 26 months need 
to be conducted in the absence of the participant’s regular PD medication (known as the OFF 
state) so that the severity of the underlying disease is evident.  
To minimise the time participants are in the OFF state and allow for withdrawal of participant’s 
PD medication, study visits should be held in the morning and participants should attend 
having omitted their prescribed short acting PD medications (e.g. Levodopa or Ropinirole 
Immediate release) from 1800 hours on the day before the visit. Long acting agents (e.g. 
Ropinirole XL) should be omitted the day before the visit and on the day of the visit itself.  
To reduce any physical discomfort of stopping PD medications and to facilitate attendance at 
clinic, the local research team should make arrangements to provide the participant with a 
prescription for relevant supportive medications (e.g. Zopiclone/Zolpidem for night sedation, 
paracetamol for pain relief and/or diazepam for treatment of dystonia) as necessary.  
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Participants may also be prescribed dispersible Madopar as a rescue medication to be taken 
in the event of severe difficulty with wearing-off symptoms. If a participant has taken 
dispersible Madopar after omitting his/her regular PD medication prior to a study visit, the 
study visit should be rescheduled. If further attempts at attending in the OFF state fail, the 
participant should be withdrawn from the study. 
3 TRIAL DESIGN 
3.1 GENERAL DESIGN 
This is a double-blind, randomised, placebo-controlled, multi-centre parallel group futility trial 
in patients with PD of moderate severity. The plan is to recruit and randomise 198 patients in 
a 1:1 ratio to receive either oral Simvastatin or matched placebo for 24 months. A one month 
low dose phase of 40mg daily will be followed by a 23 month high dose phase of 80mg daily 
and a final two month phase off trial medication. Participants will be followed up at 1 month, 
6, 12, 18, 24 and 26 months (±2 weeks) post-baseline.  Visits to obtain outcome measures 
are undertaken face-to-face, and can be either in an outpatient clinic or at home. 
3.1.1 COVID-19 Adaptions 
Following the start of the COVID-19 outbreak in early 2020, government guidelines led to a 
restriction on face-to-face trial visits. As a result, it will be necessary to conduct a small number 
of primary endpoint (24 month) visits remotely (e.g. using Skype), as well as a number of 26-
month visits.  
3.2 BLINDING 
Participants will be blind to treatment allocation throughout the trial, as will the trial 
management team, investigator site teams and site pharmacy staff. The primary statistical 
analyses of the primary outcome will be undertaken blinded to the allocated group. 
3.3 ANALYSIS POPULATIONS 
We will base the primary analysis of the primary outcome on a modified intention-to-treat 
(mITT) principle. The mITT evaluable sample for the primary analysis will include all 
participants who are randomised, provide baseline outcome data, commence to the higher 
dose phase of the study and provide 24-month outcome data. Imputation will only be 
performed for missing questionnaire items that fulfil pre-specified criteria as outlined in section 
4.10. 
To investigate any effect of compliance with taking study medication, if ≥ 20% of participants 
in the active Simvastatin group are identified as non-compliers (according to each of the 
definitions in section 4.4.2), we will undertake additional sensitivity analyses of the primary 
outcome (further details in section 7.3.1). This population will consist of all participants with 
baseline and 24-month primary outcome data. 
The safety population will consist of all participants who have at least one dose of allocated 
trial treatment. 
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A washout period has been included in the study design to explore the potential disease-
modifying effect of Simvastatin. Trial treatment will be discontinued at 24 months and a follow-
up visit is conducted two months later at 26 months post-baseline. All participants still on trial 
treatment at the higher dose of 80mg at 24 months with valid baseline, 24 and 26 months data 
will be included in the disease-modifying analysis. 
3.3.1 COVID-19 Analysis Populations 
To facilitate sensitivity analyses to explore any effect of the COVID-19 outbreak, two further 
populations are defined. The non-COVID-19 population will consist of participants whose data 
collection visits were completed on or prior to the introduction of government social distancing 
measures on 23rd March 2020. Note different numbers of participants will be included in this 
population when considering the 24 month and 26 month follow-up visits, due to the timing of 
the COVID-19 restrictions. 
The COVID-19 population will consist of participants who had one or more follow-up visits 
completed remotely. Again, the numbers of participants included in this population will differ 
for the 24 month and 26 month end-points. 
3.4 INCLUSION AND EXCLUSION CRITERIA 
3.4.1 Inclusion Criteria 
Potential participants must satisfy the following criteria to be enrolled in the study:  
 Diagnosis of idiopathic PD  
 Modified Hoehn and Yahr stage ≤ 3.0 in the ON medication state  
 Age 40-90 years  
 On dopaminergic treatment with wearing-off phenomenon  
 Able to comply with study protocol and willing to attend necessary study visits  
3.4.2 Exclusion Criteria 
Potential participants meeting any of the following criteria will be excluded from study 
participation:  
 Diagnosis, or suspicion, of other cause for parkinsonism  
 Known abnormality on CT or MRI brain imaging considered to be causing symptoms 
or signs of neurological dysfunction, or considered likely to compromise compliance 
with study protocol  
 Concurrent dementia defined by MoCA score < 21  
 Concurrent severe depression defined by MADRS score > 31  
 Prior intracerebral surgical intervention for PD including deep brain stimulation, 
lesional surgery, growth factor administration, gene therapy or cell transplantation  
 Already actively participating in a research study that might conflict with this trial  
 Prior or current use of statins as a lipid lowering therapy  
 Intolerance to statins  
 Untreated hypothyroidism  
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 End stage renal disease (creatinine clearance < 30 mL/min) or history of severe 
cardiac disease (angina, myocardial infarction or cardiac surgery in preceding two 
years) 
 Estimated Glomerular Filtration rate (eGFR) < 30 mL/min  
 History of alcoholism or liver impairment  
 Creatine kinase (CK) > 1.1 x upper limit of normal (ULN)  
 Aspartate transaminase (AST) or alanine transaminase (ALT) > 1.1 x ULN  
 Females who are pregnant or breast feeding or of child-bearing potential and unwilling 
to use appropriate contraception methods whilst on trial treatment  
 Currently taking any medication contraindicated with Simvastatin use (Appendix 2 of 
the protocol v4.5)  
 Any requirement for statin use  
 Regular participation in endurance or high-impact sports  
 Unable to abstain from consumption of grapefruit-based products 
4 STATISTICAL PRINCIPLES 
University of Plymouth medical statisticians (Peninsula Clinical Trials Unit) will carry out 
statistical analysis at the end of the study (following last participant’s last visit and database 
lock). 
4.1 RANDOMISATION, ALLOCATION CONCEALMENT AND STRATIFICATION 
The Peninsula Clinical Trials Unit (PenCTU) will provide a 24-hour web-based, 1:1 
randomisation system using random permutated blocks, stratified by site and modified Hoehn 
& Yahr stage (≤ 2.0 or 2.5 - 3.0), prepared by a statistician independent of the trial team. 
Randomisation takes place between screening and baseline visit, after confirmation of 
eligibility. Completion of the randomisation process will generate the participant’s study 
number, initials and allocated treatment bottle number for the baseline visit, which needs to 
be printed and submitted to the hospital pharmacy. 
Only members of the PenCTU programming team are able to access participants’ treatment 
allocation, except in the event of Suspected Unexpected Serious Adverse Reaction (SUSAR). 
4.2 SAMPLE SIZE CALCULATION 
In futility studies, the direction of the hypotheses is different from that in traditional phase III 
efficacy or effectiveness trials. The study sample size was based on testing the null hypothesis 
that Simvastatin is not futile, in terms of the primary outcome (change in MDS-UPDRS part III 
motor subscale score in the OFF state at 24 months). If at the end of the study there is 
evidence to reject the null hypothesis, then it is unlikely that Simvastatin will be considered for 
a phase III study, although the final decision on planning for progression to a phase III study 
will be made in discussion with the trial oversight committees and other key stakeholders.  
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The minimum clinically important difference (MCID) in UPDRS motor score has been 
estimated to be between 2.3 and 2.7 points20. The null hypothesis, 𝐻0, in this futility study is 
that the mean change in MDS-UPDRS part III score between baseline and 24 months for the 
Simvastatin group is at least 3 points less (as higher MDS-UPDRS scores are worse) than the 
corresponding mean change in the placebo group. The alternative hypothesis, 𝐻1, is that the 
mean change in MDS-UPDRS part III score for the Simvastatin group is not at least 3 points 
less than the corresponding mean change in the placebo group. Mathematically, this is written 
as  
𝐻0: 𝜇𝑠 − 𝜇𝑝 ≤ −3  versus   𝐻1: 𝜇𝑠 − 𝜇𝑝 > −3 , 
where 𝜇𝑠  is the expected mean change in MDS-UPDRS part III score from baseline to 24 
months for the Simvastatin group and 𝜇𝑝 is the expected mean change for the placebo group.  
Due to this change in the hypotheses in comparison with conventional phase III studies, the 
type I and type II error probabilities are interpreted differently compared to the traditional 
efficacy/effectiveness studies: 
 A type I error occurs when the active treatment (Simvastatin) is non-futile but is 
rejected following the futility study, leading to an effective treatment not being 
considered for a phase III study (i.e. an erroneous rejection of 𝐻0); the probability of 
this occurring is denoted by 𝛼;  
 
 A type II error occurs when the active treatment (Simvastatin) is futile but there is 
insufficient evidence to reject the null hypothesis of non-futility, and an ineffective 
treatment is considered for a phase III study (i.e. an erroneous failure to reject 𝐻0); 
the probability of this occurring is denoted by 𝛽21.  
Hence 𝛼 and 𝛽 were chosen to reflect the futility design-based hypotheses, with the one-sided 
𝛼 set at 10% and 𝛽 at 20% (i.e. 80% power). 
Based on a recently reported study at the time of the design of this futility trial, the expected 
mean increase in MDS-UPDRS part III from baseline to 12 months in the placebo group is 
assumed to be 2.2 points, with corresponding standard deviation of 7.3 points22. Assuming 
that this increase in MDS-UPDRS part III is linear over time, gives an expected mean increase 
from baseline to 24 months of 4.4 points in the placebo group (i.e. 𝜇𝑝 = 4.4). Therefore, if we 
assume the MCID is -3, this implies the mean of the Simvastatin group,  𝜇𝑠 , is 1.4 points. 
Additionally, we assume a slightly inflated standard deviation over this period of 7.5 points. 
The sample size calculation was based on a two-sample t-test with a 10% one-sided alpha. 
Following the previously listed assumptions, the number of participants needed to follow-up at 
24 months (i.e. with primary outcome data) is 57 participants per group, to provide 80% power 
to reject the null hypothesis of non-futility and declare futility.  
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This sample size was inflated to allow for a proportion of participants allocated to the 
Simvastatin group to stop taking the trial medication during the initial 1-month low dose phase. 
Assuming that this proportion was 15%, the above sample size was inflated by (1–0.15)-2, to 
give 79 participants per group23. Secondly, the sample size was adjusted to allow for a (non-
differential) loss to follow-up rate of 20%1. Accordingly, the sample size was further inflated by 
a factor of (1-0.2)-1, to give a sample size of 99 participants per group and a total recruitment 
target of 198 participants commencing the higher dose phase of the study. 
4.3 STATISTICAL SIGNIFICANCE LEVELS 
As this is a futility study, a one-sided test of the primary outcome is appropriate, which has 
been set at the 10%21 significance level. All other outcome variables will assessed on a two-
sided test at the 5% significance level with corresponding two-sided 95% confidence intervals. 
4.4 COMPLIANCE AND PROTOCOL VIOLATIONS 
4.4.1 Compliance to Allocated Treatment 
Compliance with treatment allocation is assessed throughout the study, at each visit (at 1, 6, 
12, 18, 24 months post-baseline) and telephone contacts (at 2, 4, 8, 10, 14, 16 and 22 months 
post-baseline). 
4.4.2 Protocol Violation or Deviation 
Non-compliance may occur in some instances if participants do not complete their allocated 
treatment according to the study protocol, or if the follow-up visit was not within ±2 weeks of 
the scheduled date. This could occur because of medical issues such as fatigue, deterioration 
of health, acceleration of PD, difficulty in attending outpatient clinics in the OFF state, or 
participants may simply decide that they no longer want to complete the programme.  
Within the PD STAT study protocol (section 17.9), there is allowance for study drug dose 
alterations, depending on whether the patient is at the initial low dose phase or high dose 
phase. If a participant discontinues treatment during the low dose phase, attempts will be 
made to recruit an additional participant. During the high dose phase, participants with 
unwanted symptoms/side effects may reduce to the 40mg dose and then may continue on the 
40mg dose for the remainder of the trial or, at the discretion of the local investigator, such 
participants may later be re-challenged with the 80mg dose after resolution of the unwanted 
symptoms. Participants who are on the 80mg dose and subsequently fulfil the trial stopping 
criteria will be withdrawn from treatment but invited to continue with the study assessments.  
Complete identification of compliance with the study protocol may not be possible. For 
example, there may be unreported instances where participants miss doses of their 
medication or medication containers are not returned. Compliance will be assessed based on 
a combination of each participant’s self-reported compliance during telephone calls and 
capsule count, but this may not capture the participant’s true compliance. Therefore, we will 
base compliance on the reported data, acknowledging it may have limitations. Figure 1 
outlines the possible forms of non-compliance we will be able to identify through the data 
collected. 
We have constructed two definitions of study compliance. These are: 
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(i) Participants are compliant only if they proceed to and maintain the 80mg dose and 
attend 24 month follow-up within their 2-week window of their due date, and non-
compliant if they remain on the 40mg dose, discontinue trial treatment or attend the 
24-month follow-up visit outside of the 2-week window. 
 
(ii) Participants are compliant if they take and maintain 80mg or 40mg and attend the 24 
month follow-up visit within the 2-week window of their due date, and non-compliant if 
they attend their 24-month follow-up outside of the 2-week window or discontinue trial 
treatment.  
 
Figure 1: Possible scenarios for non-compliance during the PD Stat study. Where 24m = 24 months and 2w = 2 weeks. Blue solid 
line boxes denotes compliance with the study protocol; the yellow dashed boxes denotes participants who may be considered as 
compliers or non-compliers depending on whether definition (i) or (ii) for compliance is used; the red dotted line boxes represents 
non-compliance. 
The number and proportions of participants classified as non-compliers, as defined above, will 
be summarised for each allocated group separately and overall, alongside details of the non-
compliances. A formal complier-average causal effect (CACE) analysis will proceed if at least 
20% of participants in the Simvastatin group are classified as non-compliers according, in turn, 
to each of the definitions above. Whilst non-compliance rates will be calculated and presented 
for participants allocated to the placebo group as well as participants allocated to the 
intervention group, their compliance is not relevant to the one-sided CACE analysis, in which 
non-compliance to the placebo/control does not imply receipt of the active intervention. 
There are no planned protocol deviations. Any unintended protocol deviations will be 
documented and reported to the Chief Investigator and Sponsor. The number of deviations 
and percentage (number) of participants with protocol deviations will be reported. 
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4.5 TIMING OF COLLECTION OF OUTCOME MEASURES 
Outcome measures are collected at baseline, 12 (±2 weeks), 24 (±2 weeks) and 26 (±2 weeks) 
months post-baseline. The primary endpoint is the 24-month review. Table 1 lists all the 
outcome measures, the ON or OFF state of participants when they were measured and the 
timing of these observations. 
Variable State* Baseline 
12 
months 
24 
months 
26 
months 
MDS-UPDRS Part III  
(primary outcome) 
OFF X X X X 
MDS-UPDRS Part II ON X X X X 
MDS-UPDRS Total ON X X X X 
Brain tap test OFF X X X X 
Walk Test (10MWT) OFF  X X X 
MADRS Total score ON  X X X 
ACE-III Total score ON X X X X 
NMSS Total score ON X X X X 
PDQ-39 Total score ON X X X X 
KPPS Total score ON X X X X 
EQ-5D-5L ON X X X X 
Total & HDL Cholesterol  X** X X  
LED  X X X X 
Diabetes    X  
* See section 2.3 for definition of ON/OFF states; ** Measurements taken at screening but will be referred to as baseline 
Table 1: Table of outcome measures collected and time point 
4.6 DERIVED VARIABLES 
Some of the variables to be analysed will be derived from the raw collected data. Below is a 
list of these variables and the methods to be used to derive the variables for analysis: 
 Age at baseline - calculated from date of birth and date of baseline visit. 
 
 Number of years since PD diagnosis – calculated by subtracting age of PD diagnosis 
from age at baseline. 
 
 BMI – calculated using participant’s weight in kilograms divided by their height in 
metres (kg/m2). 
 
 MDS-UPDRS part III score – the sum of all 33 items within part III of MDS-UPDRS, 
giving a possible score between 0 and 132. 
 
 MDS-UPDRS part II score – the sum of all 13 items within part II of MDS-UPDRS, 
giving a possible score between 0 and 52. 
 
 MDS-UPDRS total score – the sum of all 65 items of the MDS-UPDRS, giving a 
possible score between 0 and 260. 
 
 Brain tap test – mean frequency key taps of left and right hand. 
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 10MWT – a binary outcome of whether participant was able to complete at least one 
10MWT and mean time for participant to complete a 10MWT calculated from all 
successfully completed attempts. 
 
 MADRS Total score – the sum of all 10 items, giving a total score between 0 and 60.  
 
 ACE-III Total score – the score from each of the five subdomains, where the score for: 
attention is 0-18; memory is 0-26; fluency is 0-14; language is 0-26 and visual spatial 
is 0-16. The total score is then a value between 0 and 100.  
 
 NMSS Total score – for each item, the severity is multiplied by frequency, resulting in 
an item sub-score of 0 to 12. Each item is then summed, giving a total score between 
0 and 360. 
 
 PDQ-39 Total score – the total scores from each of the eight dimensions are converted 
into a scale from 0 (best) to 100 (worst) by dividing by the maximum possible score of 
that dimension and then multiplying by 100. The total overall PDQ-39 score is then 
calculated by summing the eight dimension total scores and then dividing by 8. 
 
 Total/HDL Cholesterol ratio – total cholesterol level divided by HDL. 
 
 KPPS Total score – for each of the 14 items amongst the seven domains, the severity 
(scored as 0 to 3) is multiplied by the reported frequency (scored as 0 to 4), resulting 
in an item sub-score of 0 to 12. The 14 items are then summed, giving a total score 
between 0 and 168. 
 
 EQ-5D-5L – the crosswalk24 of the score to EQ-5D-3L will be calculated. 
 
 LED – calculation of the LED will depend on the conversion factor, listed in Appendix 
A: Table 4, taken from Tomlinson, et al. 25 and Cervantes-Arriaga, et al. 26, where the 
daily dose in mg of the medication is multiplied by the conversion factor.  
4.7 INTERIM ANALYSIS 
There is no planned interim analysis in this study. 
4.8 TIME POINTS OF STATISTICAL ANALYSIS 
Statistical analysis will be performed after the final assessment of the last participant has been 
submitted and the trial database has been locked. 
4.9 DATA SOURCES AND DATA QUALITY 
The research nurse or other member of the research team will check completed case report 
forms (CRFs) for missing data or obvious errors before forms are sent to the CTU. Data will 
be monitored centrally for quality and completeness by the CTU and every effort will be made 
to recover data from incomplete forms where possible. The CTU data manager will oversee 
data tracking and data entry and initiate processes to resolve data queries where necessary. 
The CTU trial manager will devise a risk-based monitoring plan specific to the study, which 
will include both central monitoring strategies and study site visits as appropriate. 
 
 
 
 
 
PD STAT SAP V2.1 24082020 Page 21 of 48 
 
 
If there is evidence of fraudulent data, this will be considered a major non-compliance. 
Potential fraudulent data will be: 
 Noted in the final report 
 Summarised  
Consideration will be given to excluding all data for any site where fraudulent data is suspected 
or detected. 
4.10 MISSING DATA 
Data for participants who miss follow-up visits will not be imputed. The timing and frequency 
of missing data will be summarised. 
4.10.1 Missing Primary Outcome Data 
Summary statistics of the number of missing items, and frequencies and percentages of 
participants with missing items of the MDS-UPDRS part III score will be reported.  
Provided all missing items of MDS-UPDRS part III are missing at random, the total score for 
a given participant can be imputed if a maximum of seven of the 33 possible items are missing. 
Alternatively, if the same item is missing across all participants for one follow-up time-point, a 
maximum of three items can be missing to allow for valid imputation of the total score for each 
participant27.  
In PD STAT, one item of the MDS-UPDRS part III was erroneously omitted from case report 
forms at all time-points. Question 15 should consist of two items, a score for postural tremor 
for each of the left and right hands. However, only one item response could be recorded and 
the case report form did not specify, or request specification of, which hand. For a small 
proportion of participants, the assessor manually annotated the case report forms and 
included postural tremor scores for the left and right hand. In these instances, the scores for 
both left and right hands will be used as part of the calculation of the primary outcome. 
However, if a participant only has one postural tremor score, the second postural tremor 
score will be treated as missing data (not at random).  
For a maximum of three missing items, imputation of the MDS-UPDRS part III total score will 
be undertaken according to the following equation 
𝐷 =
𝐴 × 𝐵
𝐶
 
Equation 1 
where 𝐴 is the sum of the items scored, 𝐵 is the total number of items which should have been 
scored (for MDS-UPDRS part III B = 33), 𝐶 is the number of items actually scored and 𝐷 is 
the imputed score (i.e. total MDS-UPDRS part III score). 
For the purposes of pre-defined sensitivity analyses of the primary outcome (outlined in 
section 7.3), the requirement of no more than three missing items will be relaxed. 
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4.10.2 Other Missing Data 
If there are validated methods for imputing missing items in self-reported secondary outcomes, 
these will be used to impute total scores. Details of imputation methods to be used to handle 
missing data can be found in Appendix A: Table 5. 
4.10.3 Missing Data as a Consequence of COVID-19 
Although the majority of outcomes can be completed remotely, due to the nature of some of 
the tasks, a small number of items/measurements cannot be assessed during remote visits. 
For the MDS-UPDRS part III, question 3 (rigidity, consisting of 5 items) and question 12 
(postural stability, consisting of 1 item) cannot be assessed remotely. This will affect 
calculation of the primary outcome, total MDS-UPDRS part III assessed in the OFF state, and 
corresponding secondary outcome assessed in the ON state.  
In addition, the ACE-III cannot be completed remotely, whilst completion of 10MWT is 
dependent on the suitability of the participant’s house or outside space and completion of the 
BTT is dependent on a stable internet connection and the availability of a tablet or computer. 
Finally, outcomes derived from the blood test at 24 months will be missing for participants in 
the COVID-19 population. 
5 STUDY POPULATION 
Data from the screening process through to the completion of the trial will be recorded and 
presented in a CONSORT-style flow diagram (see Figure 4 in Appendix B). In particular, the 
following data will be provided: 
 Number of participants screened for eligibility 
 Number of participants ineligible* 
 Number of participants eligible and asked to participate 
 Number of participants who declined to participate* 
 Number of participants consented to participate 
 Number of participants withdrawn prior to randomisation* 
 Number of participants randomised to each allocated group 
 Number of participants who did not receive their allocated treatment* 
 Number of participants who did receive their allocated treatment 
 Number of participants who progressed to the higher dose 
 Number of participants who did not progress to the higher dose* 
 Number of participants who did not complete their allocated treatment* 
 Number of participants who completed their allocated treatment 
 Number of participants who completed each of the 12, 24 and 26 month follow-up 
visits 
 Number of participants lost to follow up* 
 Number of participants analysed 
*Reasons will be provided where available. 
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5.1 PARTICIPANTS WHO DISCONTINUE, WITHDRAW OR ARE LOST TO FOLLOW-
UP 
All participants will be encouraged to continue with study visits and assessments as per the 
study protocol even if trial treatment is discontinued prematurely. If a participant discontinues 
in the first 1-month low dose phase, attempts will be made to recruit additional participants to 
supplement participants who discontinue treatment during the first phase, even if they are 
continuing with the follow-up visits. The number of participants who are recruited due to an 
earlier participant discontinuing trial treatment during the 1-month low dose stage will be 
reported.  
Participants who discontinue allocated treatment will be categorised into one of the following: 
 Continue to consent for follow-up and data collection 
 Consent to use pre-collected data only 
 No further follow-up and withdraw consent to use data already collected 
Reasons for withdrawal or loss to follow up will be summarised where possible, at each stage 
of the trial (withdrawal prior to randomisation, patients who did not receive their allocated 
treatment, non-completion of treatment, lost to follow-up). 
5.2 BASELINE CHARACTERISTICS AND DEMOGRAPHICS 
The demographic data will include: 
 Age in years at baseline 
 Gender 
 Body Mass Index (BMI) 
 Ethnic origin 
 Smoking status 
 Modified Hoehn & Yahr score 
 Age in years of PD onset 
 Number of years since PD diagnosis at baseline 
 Diabetes status at screening 
 QRISK® 2 score 
 Montreal Cognitive Assessment Score (MoCA) 
 Aspartate transaminase (AST) 
 Alanine transaminase (ALT) 
 Creatine kinase (CK) 
The data will be summarised using descriptive statistics for all recruited participants. 
Summaries will be produced for participant’s who only participate in the 1-month low dose 
phase of the study. 
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6 STATISTICAL ANALYSES 
6.1 GENERAL CONSIDERATIONS  
Descriptive statistics will be presented for all outcomes at all available time points. For 
continuous outcomes, summary statistics will be presented in the form of means (including 
mean difference between follow-up and baseline where appropriate) alongside standard 
deviations and ranges, or other suitable summary statistics such as medians and inter-quartile 
range, depending on the distributional properties of the variable. For categorical outcomes, 
summary information will be presented in the form of frequencies and percentages.  
The primary analysis of the primary outcome will be presented with a one-sided p-value and 
two-sided 80% confidence interval (see 7.2.1 for further details). Analyses of the secondary 
outcomes will be presented with two-sided p-values and two-sided 95% confidence intervals 
wherever possible. If the evidence suggests modelling the raw measurements of the primary 
outcome is inappropriate, bootstrapped confidence intervals of the between-group differences 
will be presented. If the model assumptions for a secondary outcome are violated, an 
appropriate transformation of the outcome will be sought or alternatively the between-group 
difference will be presented alongside the bootstrapped confidence interval.  
6.2 ADJUSTMENTS 
The primary analysis of the primary and secondary outcomes will include fixed effects 
adjustments baseline outcome, gender, age at baseline and modified Hoehn and Yahr score28. 
Recruiting site will be included as a random effect in order to account for any potential 
unknown variation associated with each site. 
In addition to the adjustments specified in the protocol, we will also include duration of PD, as 
recent evidence suggests that the rate of change in MDS-UPDRS differs according to disease 
duration29. If there is a suggestion from a visual inspection of any large difference in any of the 
other baseline characteristics/ demographics between allocated groups, sensitivity analysis 
will include additional adjustments for such a covariate. 
For completeness and in line with EMA guidance30, the results of models only including 
adjustment for baseline scores (where available) will also be presented. 
6.3 STATISTICAL SOFTWARE 
The data will be analysed using STATA (version 14 or above)31 and supplemented with R32 
where necessary. 
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6.4 REPORTING CONVENTIONS 
P-values ≥ 0.001 will be reported to three decimal places; p-values less than 0.001 will be 
reported as “< 0.001”. The mean, standard deviation, and any other statistics other than 
quantiles, will be reported to one decimal place greater than the original data. Quantiles, such 
as median, or minimum and maximum, will use the same number of decimal places as the 
original data. Estimated parameters not on the same scale as raw observations (e.g. 
regression coefficients) will be reported to three significant figures.  
7 ANALYSIS OF THE PRIMARY OUTCOME 
7.1 OUTCOME VARIABLE 
The primary outcome is the change in MDS-UPDRS part III in the OFF state between baseline 
and 24 months. The total score is calculated from the 33 items within the MDS-UPDRS part 
III, where each item is scored between 0 and 4. 
7.2 PRIMARY ANALYSIS: FUTILITY ANALYSIS 
The aim of the primary analysis is to determine whether Simvastatin is clearly ineffective 
(futile) in preventing the decline of PD. This will be achieved by a between-group comparison 
of change in MDS-UPDRS part III from baseline to 24 months, measured in the OFF state.  
Specifically, a mixed-effects linear regression model will be fitted to the change in MDS-
UPDRS part III scores between baseline and 24 months (𝑦), for participants 𝑗 = 1, … , 𝑛𝑖, from 
site 𝑖 = 1, … , 23 of the form: 
𝑦𝑖,𝑗 = 𝛿𝑠𝑥1,𝑖,𝑗 + 𝜽𝒙𝑖,𝑗 + 𝑍𝑖 + 𝑖,𝑗 
Equation 2 
where 𝑥1 is an indicator variable for allocated group and 𝛿𝑠 is the mean difference between 
treatment groups. The vector 𝒙𝑖,𝑗 represents the row of the design matrix for participant 𝑗 from 
site 𝑖, where the first element is 1 and the subsequent elements are the fixed effects covariates 
defined in section 6.2, with corresponding coefficient vector 𝜽. The random effects (recruiting 
sites) are represented by 𝑍𝑖  ~ 𝑁(0, 𝜎𝑧
2) and 𝑖,𝑗 ~ 𝑁(0, 𝜎𝜀
2) are the individual-level residual 
errors. 
7.2.1 Interpretation of the results of the primary analysis  
The primary analysis aims to determine the futility, or otherwise, of Simvastatin with respect 
to the primary outcome. Recall the hypotheses in section 4.2: 
𝐻0: 𝜇𝑠 − 𝜇𝑝 ≤ −3  versus   𝐻1: 𝜇𝑠 – 𝜇𝑝 > −3. 
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Testing of this will be achieved by determining whether the adjusted treatment coefficient 
estimate, 𝛿𝑠 from Equation 2, is less than or equal to -3, based on the test statistic from chapter 
8 in Ravina, et al. 33: 
𝛿𝑠 − (−3)
𝜎𝑠
 ~ 𝑡𝜂 
Equation 3 
where σs is the standard error for the estimated coefficient and t is student’s t distribution with 
𝜂 degrees of freedom. The degrees of freedom (𝜂) is calculated from the total sample size 
minus the number of treatment groups minus number of adjustment covariates. The p-value 
for this test is determined by examining the upper tail of student’s t-distribution. Possible 
scenarios for the futility analysis of Simvastatin are presented in Figure 2. 
 
Figure 2: Possible scenarios for observed group differences in the change of MDS-UPDRS between baseline and 24 months 
under the assumptions of a futility analysis. The black circles are the between group differences in change in UPDRS at 24 
months (point estimate). The red lines are two-sided 80% confidence intervals if the study is futile (i.e. p < 0.1) and blue lines are 
two-sided 80% confidence interval if the study is non-futile (i.e. p ≥ 0.1).  The dashed grey line at -3 is the pre-specified minimal 
clinically important difference. The dotted grey line at CV is the critical value from student’s t-distribution; the point estimate should 
be above this value (to the right of this line) to demonstrate futility. 
If the p-value is less than 0.1, then the null hypothesis (that Simvastatin is not futile) will be 
rejected and Simvastatin will not be recommended for a phase III study. If the p-value is 
greater than 0.1 then there is insufficient evidence to reject the null hypothesis that Simvastatin 
is not futile.  
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P-value 80% Confidence Interval Recommendations 
~ 0.1 Does not contain -3 Consider Simvastatin futile. 
≥ 0.1 Contains -3 
 𝛿𝑠 >  −3: Consider Simvastatin not futile 
 𝛿𝑠 ≤  −3: Consider further analysis of 
collected data for superiority. 
>> 0.1 Upper bound below -3 
Consider further analysis of collected data for 
superiority. 
Table 2: Suggested recommendations based on the results of the futility analysis of the primary outcome if the null hypothesis 
is not rejected. 
 
In addition to considering the calculated p-value, it is important to consider the two-sided 80% 
confidence interval to aid in interpreting the results of the primary analysis. Recommendations 
based on the two-sided 80% confidence interval, if the p-value is 0.1 or greater, are outlined 
in Table 2. However, these recommendations may require additional consideration should the 
original assumptions made for the sample size calculation prove to be invalid. The final 
decision on the futility or otherwise of Simvastatin should also take into consideration the 
results from the secondary outcomes and safety analysis. 
7.3 SENSITIVITY ANALYSES OF THE PRIMARY OUTCOME 
Inferential sensitivity analyses will only be performed if the pre-specified criteria outlined in 
each of the following sections are met. Otherwise, appropriate descriptive statistics of the 
primary outcome by compliance (according to the pre-specified definitions given in section 
4.4.2) will be presented.  
7.3.1 Non-Compliance Sensitivity Analysis 
Frequency and percentages of non-compliers for each of the compliance definitions outlined 
in section 4.4.2 will be reported. If ≥ 20% of participants with 24-month outcome data are 
classed as non-compliers based on either compliance definition (i) or definition (ii) from section 
4.4.2, a sensitivity analysis based on that definition will be triggered. Therefore, a maximum 
of two non-compliance sensitivity analyses will be performed.  
One potential method for sensitivity analyses is a per protocol analysis, which would only 
analyse participants who completed the trial as indicated in the protocol. However, this 
approach could introduce bias by excluding participants after randomisation and thus 
jeopardising the group comparability achieved through randomisation.  
As an alternative, a complier-average causal effect (CACE) analysis will be undertaken if 
triggered according to the criteria above, which will provide an unbiased estimate of the 
intervention effect, based on protocol compliance34. In a CACE analysis, participant’s allocated 
group is included in the model as an instrumental variable and the participant’s given treatment 
is an endogenous variable, which will consist of placebo or intervention. The definitions of 
compliance in section 4.4.12 will be used to determine the participants’ given treatment.  
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Under compliance definition (i), intervention participants’ given treatment (the endogenous 
variable) would remain as intervention only if they proceeded to and maintained the 80mg 
dose and attended their 24-month follow-up assessment within the 2-week window. If they did 
not proceed to the 80mg dose, or if they did not attend their 24-month follow-up within the 2-
week window, they would be classed as non-compliers and their given treatment would be 
classified as placebo. 
Compliance definition (ii) is less stringent than compliance definition (i); participants in the 
intervention group will be classed as compliers and their given treatment will remain as 
intervention even if they do not proceed to the 80mg dose, provided they attend their 24-month 
assessment within the 2-week window and at least remain on the 40mg dose. Otherwise, their 
given treatment will become placebo. 
It is possible that participants may be prescribed a statin, if clinically indicated, external to the 
study, at which point their allocated trial treatment will be discontinued, but they will be eligible 
to continue with follow-up. For participants allocated to the intervention who are prescribed 
statins at least equivalent to the study treatment (80mg under compliance definition (i); 40mg 
under compliance definition (ii)), their given treatment will remain as intervention; otherwise, 
their given treatment will be specified as placebo. In circumstances where a placebo allocated 
participant is prescribed statins within three months of commencing the study (i.e. minimum 
of 21 months on clinically indicated statin) and provides primary outcome data at 24 months, 
a clinical decision will determine whether the prescribed statin is equivalent to either 80mg or 
40mg of Simvastatin.  
If the clinical decision indicates the prescribed statin is at least equivalent to either dose of 
study treatment, the participant’s given treatment will change to intervention accordance to 
the compliance definition; otherwise, they will remain as placebo.  
With the exception of clinically indicated statin prescription outlined previously, under both 
compliance definitions, the given treatment of non-compliant participants allocated to the 
placebo arm will remain as placebo. 
As a consequence of the planned CACE analyses, the group allocations will have to be known 
in order to identify non-compliers in the intervention group. Therefore, this analysis will be 
conducted following completion of the primary analysis of the primary outcome, once the 
statistician is unblinded. 
Interpretation of the results from the CACE analyses will be based on testing the one-sided 
futility hypothesis, as detailed in section 7.2. 
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7.3.2 Location of Face-to-Face Visit Sensitivity Analysis 
Participants’ face-to-face visits could be conducted in an outpatient clinic or at home. To 
determine if the location of the visit has an effect on the primary outcome, irrespective of the 
group allocation, a sensitivity analysis will be performed in which the location of visit is included 
as a fixed effect covariate, alongside the previously defined adjustments in section 6.2. This 
fixed effect covariate will have four levels: (i) baseline and 24 month follow-up visit in clinic; (ii) 
baseline visit in clinic, 24 month follow-up visit at home; (iii) baseline visit at home, 24 month 
follow-up visit in clinic and (iv) both visits at home.  Visits completed not face-to-face (i.e. visits 
completed remotely due to COVID-19 outbreak) will be excluded from this sensitivity analysis.  
7.3.3 COVID-19 Sensitivity Analysis 
The EMA draft guidance35 on the implications of COVID-19 on methodological aspects of 
ongoing trials recommends additional analyses are undertaken to investigate three key 
phases (pre, during and post COVID-19), in order to understand the impact of the outbreak 
on the estimated treatment effect. As PD-STAT was nearing completion at the start of the 
outbreak, only two of these phases (pre and during COVID-19) will be applicable. 
The primary outcome, MDS-UPDRS part III scores in the OFF state at 24 months, will be 
imputed as described in section 4.10.1, despite the fact that there will be more than three 
items missing for participants assessed during the COVID-19 lock down, due to the limitations 
of remote data collection outlined in 4.10.3. In order to facilitate a fair comparison between the 
COVID-19 and non-COVID-19 populations (defined in section 3.3.1), two models will be fitted 
to all participants’ imputed total scores for (i) the COVID-19 population and (ii) the non-COVID-
19 population. Interpretation of the analysis will focus on informal comparison of the coefficient 
estimates of allocated group difference between each model. 
7.4 SECONDARY ANALYSES OF THE PRIMARY OUTCOME 
7.4.1 Repeated Measure Model 
To ensure maximal use of the available primary outcome data, a repeated measures, mixed 
effects model36 will be fitted to the primary outcome measure at baseline, 12, and 24 months, 
where participants are included as a random effect.  
The model will be adjusted for participant’s age at baseline, gender and disease duration, as 
well as the stratification variables (Hoehn & Yahr score as a fixed effect and recruiting site as 
a random effect). The model will include visit (baseline, 12 months and 24 months) and the 
interaction between visit and allocated group, which will be the coefficient of interest.  
The repeated measure model is defined as 
𝑦𝑖,𝑗,𝑡 = 𝛿1𝑡 + 𝛿2𝑥1,𝑖,𝑗𝐼𝑡=12 + 𝛿3𝑥1,𝑖,𝑗𝐼𝑡=24 + 𝜽𝒙𝑖,𝑗 + 𝑍𝑖 + 𝑈𝑖,𝑗 + 𝑖,𝑗,𝑡. 
Equation 4 
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where  
 𝐼𝑡=𝑘 = {
0 if 𝑡 ≠ 𝑘
1 if 𝑡 = 𝑘
  for 𝑘 = 12, 24 is the visit month 
 𝑦𝑖,𝑗,𝑡 is the MDS-UPDRS score at visit month 𝑡 
 𝛿1 is the slope coefficient for time 𝑡 
 𝛿2 is between group difference at 12 months 
 𝛿3 is the between group difference at 24 months 
 𝑈𝑖,𝑗 ~ 𝑁(0, 𝜎𝑢
2)  is the random effect for participant 𝑗 in cluster 𝑖, independent of 𝑍i 
 𝑖,𝑗,𝑡  ~ 𝑁(0, 𝜎𝜀
2)  is the individual residual error at month 𝑡. 
The terms 𝑥1, 𝒙𝑖,𝑗, 𝜽, 𝑍𝑖, 𝑖 and 𝑗 are the same as defined for Equation 2, except the baseline 
score which is now included as an outcome instead of a fixed effect covariate. 
7.4.2 Disease-Modifying Analysis 
If there is evidence from the primary analysis that Simvastatin is not futile, consideration will 
be given to performing additional analysis of the primary outcome to investigate a potential 
disease-modifying effect. Descriptive statistics (e.g. means and 95% CI) and plots of MDS-
UPDRS part III by visit month and allocated group will be presented. Participants will be 
included in the disease modifying analysis if: (i) they have fully complied with the treatment 
protocol (i.e. definition (i) from section 4.4.2) and (ii) they have provided valid MDS-UPDRS III 
scores at least two time points according to the imputation requirements outlined in section 
4.10.1. 
A mixed effects, repeated measures model will be fitted to the primary outcome measured at 
baseline, 12, 24 and 26 months, with participants included as a random effect. This repeated 
measures model will allow for missing data, whilst also allowing for analysis of the two-period 
design of the washout phase37.  
Adjustments will also be made for the stratification variables, modified Hoehn & Yahr score as 
a fixed effect and recruiting site as a random effect, as well as patient-related factors, which 
may have a strong influence on disease progression, i.e. disease duration, gender and age at 
baseline, to account for potential influence on the primary outcome38. 
The repeated measure model to investigate a disease modifying effect is defined as 
𝑦𝑖,𝑗,𝑡 = 𝛿
12∗𝑥1,𝑖,𝑗𝐼𝑡=12 + 𝛿
24∗𝑥1,𝑖,𝑗𝐼𝑡=24 + 𝛿
26∗𝑥1,𝑖,𝑗𝐼𝑡=26 + 𝛿1𝑡 + 𝜽𝒙𝑖,𝑗 + 𝑍𝑖 + 𝑈𝑖,𝑗 + 𝑖,𝑗,𝑡 
Equation 5 
where δ𝑘∗ is the allocated group difference at the 𝑘  visit month. The terms 𝑦𝑖,𝑗,𝑡, 𝑥1, δ1, 𝒙𝑖,𝑗, 𝜽, 
𝑍𝑗, 𝑈𝑖,𝑗, 𝑖,𝑗,𝑡, 𝐼t=𝑘 , 𝑖 and 𝑗 are the same as defined in Equation 4, but  𝑘 = 12, 24, 26, which 
include the 26-month visit and excludes baseline.   
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The study is not powered to determine whether the treatment is disease modifying. Therefore, 
the results of this analysis should be treated with caution, and interpreted as exploratory only. 
However, interpretation will focus on δ26∗, where an estimate below zero may be indicative of 
a effect that persists after discontinuation of treatment, suggesting the possibility that the effect 
of simvastatin is disease modifying rather than merely symptomatic.  
The duration of the washout period of two months was a pragmatic decision. Currently there 
is no literature defining an appropriate washout period that would ensure any potential 
symptomatic effect of Simvastatin on PD had completely disappeared. 
7.4.2.1 Disease-Modifying COVID-19 Sensitivity Analysis 
To ascertain the possible impact of COVID-19 on the results of the disease-modifying analysis, 
a sensitivity analysis will be performed. The repeated measure model defined in Equation 5 
will be fitted to the MDS-UPDRS part III scores in the OFF state, with imputation of the total 
scores undertaken regardless of the number of missing items, and will include an indicator 
variable that identifies whether the visit was completed during COVID-19 lockdown. The 
estimated coefficient and associated 95% confidence interval of the COVID-19 indicator 
variable will be used to understand the effect of COVID-19 on the disease-modifying analysis. 
7.5 SUPERIORITY ANALYSIS 
If there is clearly insufficient evidence to conclude futility, there is potential for analysis of the 
primary outcome to assess superiority (see Appendix C for correspondence).  
Recall the null hypothesis for the futility design from section 4.2:  
𝐻0: 𝜇𝑠 − 𝜇𝑝 ≤ −3. 
This is the pre-specified superiority. Now consider the null hypothesis of a superiority design 
(i.e. zero treatment effect),  
𝐻0
(𝑠)
: 𝜇𝑠 − 𝜇𝑝 = 0. 
These two parameter subspaces are mutually exclusive, such that if one null hypothesis is 
true the other must be false. Therefore, at most only one type I error can ever be committed, 
whatever the nature of the true state may be. We conclude there is no need to adjust for type 
I error rate inflation, and there are no multiple testing issues associated with a further 
superiority analysis. A visual example of potential confidence intervals, for both futility and 
superiority analyses, are presented in Figure 3. 
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Figure 3: Possible scenarios for observed group differences in the change of MDS-UPDRS between baseline and 24 months 
under the assumptions of a futility and superiority analysis. The black circles are the difference between group means (point 
estimate). The red lines are two-sided 80% confidence intervals if the study is futile (i.e. p < 0.1) and blue lines are two-sided 
80% confidence interval if the study is non-futile (i.e. p ≥ 0.1). The green lines are the 95% confidence interval estimated with the 
same data under the assumptions for a superiority analysis. The dashed grey line at the MCID is the minimal clinically important 
difference. The dotted grey line at CV is the critical value from student’s t-distribution; the point estimate should be above value 
(to the right of this line) to demonstrate futility. 
 
8 ANALYSIS OF SECONDARY OUTCOMES 
8.1 SECONDARY OUTCOME VARIABLES 
Where available, the secondary outcomes will be analysed:  
(i) at 24 months; 
 
(ii) using repeated measures modelling to include data at baseline, 12 and 24 months. 
A list of the secondary outcomes, whether the patient was measured in the ON or OFF state 
and the objective of the measures are presented in Table 3. 
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Outcome State Objective 
MDS-UPDRS part II ON Impact on motor experiences of daily living 
MDS-UPDRS Total ON Impact on burden and extent of PD 
Brain tap test  
(number of key presses in 30 
seconds) 
OFF Impact on timed motor test 
10MWT  
(successfully completed and 
mean time to complete) 
OFF 
Impact on timed motor test and distinguish 
symptomatic from disease modifying effects  
MADRS Total score ON Impact on mood 
ACE-III Total score ON Impact on cognitive abilities 
NMSS Total score ON Impact on non-motor symptoms 
KPPS Total score ON Impact on non-motor symptoms 
PDQ-39 Total score ON Impact on activities of daily living 
Total cholesterol level   Safety of Simvastatin 
HDL cholesterol level  Safety of Simvastatin 
Total/HDL cholesterol ratio  Safety of Simvastatin 
Incidents of diabetes at 24 
months 
 Safety of Simvastatin 
LED 
 Distinguish symptomatic from disease modifying 
effects 
Number of capsules every 6 
months 
 Tolerability of simvastatin and trial protocol 
Table 3: Secondary Outcomes and the objectives they will be used to assess. 
8.2 SECONDARY OUTCOMES ANALYSIS 
Continuous secondary outcome measures will be analysed:  
(i) at 24 months using mixed effects, linear regression models; 
 
(ii) across baseline, 12 and 24 months using repeated measures linear models.  
Since incidence of diabetes is a binary measure only observed at 24 months, this secondary 
outcome will be modelled using a mixed effects logistic regression model.  
The models will be adjusted by the covariates described in section 6.2, with the exception of 
the repeated measures models, which will not include the baseline measure as a covariate 
(as baseline data are included in the outcome being modelled). 
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As not all participants will be able to complete the 10MWT, the ability to complete the test, as 
well as the time, are both valuable indicators of PD progression. Therefore, we will analyse 
time and successful completion of the 10MWT as two components of this outcome measure.  
We will model completing the 10MWT as:  
 binary data – whether participant successfully completed at least one 10MWT (yes or 
no); 
 continuous data - mean time, of participants who are able to complete at least one 
10MWT. 
The number of capsules and percentage of expected capsules returned every month will be 
reported for both of the allocated groups. 
The secondary outcomes will not be tested under a futility hypothesis framework: allocated 
group differences will be assessed at the two-sided 5% level of significance and reported with 
two-sided 95% confidence intervals. As the trial is not powered to detect clinically meaningful 
differences on the secondary outcome measures, and no adjustments for multiplicity will be 
made, the results of the analyses of secondary outcomes will be interpreted and reported as 
exploratory only.  
8.2.1 COVID-19 Sensitivity Analyses of Secondary Outcomes 
In line with the draft guidance on the implications of the COVID-19 outbreak on methodological 
aspects of ongoing clinical trials35, additional sensitivity analyses of all secondary outcomes 
for which at least one participant provided valid 24-month data during COVID-19 lockdown will 
be undertaken. Specifically, the analyses of each of the secondary outcomes will be repeated 
excluding participants who provided 24-month outcome data during COVID-19 lockdown 
when social distancing measures were in place (i.e. the non-COVID-19 population). 
Comparison of the treatment effect estimates from these sensitivity analyses against the 
estimates obtained from the primary analyses of the secondary outcomes will facilitate 
informal evaluation of the effect of the pandemic on the secondary outcomes.  
The number of capsules and percentage of capsules returned every month will also be 
presented according to whether 24-month outcome data was collected face-to-face or 
remotely.  
9 SAFETY DATA 
Adverse event (AE) data gathered from telephone contacts and visits of participants included 
in the safety population will be used to determine the safety and tolerability of Simvastatin.  
The number and percentage of adverse events (AEs) will be reported by participant’s 
completion status (i.e. completed IMP, discontinued IMP and withdrew) and by treatment 
taken (i.e. placebo, 40mg only or 80mg). We will also report information on: 
 Timing of withdrawal/discontinuation 
 Severity of AEs prior to withdrawal/discontinuation 
 Classification of AEs prior to withdrawal/discontinuation 
 Whether the decision to withdraw/discontinue was blinded. 
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We will report summary statistics of AEs by treatment taken, and if the number of participants 
reporting at least one AE within an organ system classification exceeds 5% of the safety 
population, we will report the AE summary statistics by treatment taken for that particular organ 
system. The summary statistics of serious adverse events (SAEs) will be reported by 
treatment taken and organ system classification.  
Any AEs and/or SAEs which are related to common known effects side of statins use, as listed 
in the BNF 39, will be reported by treatment taken. These include: 
 Asthenia 
 Constipation 
 Diarrhoea 
 Dizziness 
 Flatulence 
 Gastrointestinal discomfort 
 Hepatitis 
 Headache 
 Myalgia 
 Myopathy (including myositis) 
 Nausea 
 Sleep disorder 
 Thrombocytopenia 
The summary statistics of AEs and SAEs will include: 
 Numbers and percentages of participants reporting at least one AE 
 Numbers and percentages of participants reporting AEs by the total number of AEs 
participants have reported 
 Numbers and percentages of participants reporting at least one SAE 
 Numbers and percentages of participants reporting SAEs by the total number of SAEs 
participants have reported 
In addition, we shall produce Kaplan-Meier curves of cumulative incidences of AEs and SAEs 
by treatment taken. 
Although no formal hypothesis testing of the safety data will be conducted, 95% confidence 
intervals of proportions by treatment taken will be presented. Any notable increase in safety 
related events within the Simvastatin groups (40mg only or 80mg) compared to the control 
group will be investigated further. 
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APPENDIX  
A. ADDITIONAL INFORMATION FOR OUTCOME MEASURES 
 
PD Medication Conversion Factor 
Amantadine 1 
Apomorphine 10 
Azilect 10 
Bromocriptine 10 
Cabergoline 80 
Duodopa 1.11 
Entacapone 0.33* 
Levodopa dispersible 1 
Levodopa immediate release 1 
Levodopa controlled release 0.75 
Lisuride 100 
Madopar 1 
Mirapex 100 
Opicapone 0.5* 
Pergolide 100 
Pramipexole 100 
Rasagiline 100 
Requip 20 
Ropinirole 20 
Rotigotine 30 
Rytary 0.6 
Safinamide 100** 
Selegiline Oral 10 
Selegiline Sublingual 80 
Sinemet 1 
Sinemet controlled release 0.75 
Stalevo 0.33* 
Tolcapone 0.5* 
* Multiply immediate release levodopa dose by conversion factor and add to immediate release levodopa dose. 
** Add this value to the LED, regardless of dose. 
Table 4: Conversion factors for levodopa-equivalent dose 
Example: Immediate release Levodopa dose = 400 and Entacapone = 800, implies:  
LED = (1 × 400) + (0.33 × 400) = 400 + 132 = 532 
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Secondary  
outcome 
Missing Items 
MDS-UPDRS 
part II  
Goetz, et al. 27  
Imputation formula 
𝐷 =
𝐴 × 𝐵
𝐶
 
 𝐴 - sum of the items scored, 
 𝐵 - total number of items which should have been scored 
 𝐶 - number of items with actual score  
 𝐷 - imputed score. 
Part I missing a maximum of 1 item, part II missing maximum of 2 
items, part III missing maximum of 3 items, part IV cannot have any 
missing items. 
MDS-UPDRS 
Total  
MDS-UPDRS 
part IV 
For questions 1, 3 and 6, the score is based on the percentage reported 
in part C of each question, which is calculated by dividing the number 
of hours stated in part B by the number of hours stated in part A and 
multiplying by 100. For each of questions 1, 3 and 6, the question score 
is then:  
 0 if part B = 0 
 1 if part C ≤ 25% 
 2 if part C is 26-50% 
 3 if part C is 51-75% 
 4 if part C > 75%. 
In instances where the ordinal score is missing but part C (the 
percentage) is available, the score will be determined based on the 
above thresholds of the reported part C. If the ordinal score and part C 
are missing but part A and B are available, part C (the percentage) will 
be calculated and the ordinal score determined by the above defined 
thresholds.  
MADRS 
For a maximum of 1 missing item 
Use weighted means from Gale and Hawley 40 to calculate total 
MADRS score, see Table 6 for weights. 
ACE-III 
Participants with any missing items set total score to missing 
(approach 3, Lees, et al. 41). 
PDQ-39 Use EM algorithm but requires more than 200 participants42. 
Table 5: Methods for handling missing items for questionnaire data, where available 
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Item Weight 
1 1.03 
2 1.14 
3 1.13 
4 1.20 
5 0.69 
6 1.18 
7 1.15 
8 1.11 
9 0.89 
10 0.47 
Table 6: Item weights for the calculation of MADRS given one item is missing 
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B. EXAMPLES OF FIGURES AND TABLES FOR REPORTING STUDY RESULTS 
 
 
Figure 4: CONSORT Flow Diagram of participants through PD STAT. 
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 Simvastatin 
N (%) 
Placebo 
N (%) 
All 
N (%) 
Age in years    
Mean (SD) [range]    
Median (IQR)    
Female    
Ethnic Origin    
     White    
     Black Caribbean    
     Black African    
     Chinese    
     Indian    
     Pakistani    
     Bangladeshi    
     Other    
Smoking Status    
     Non smoker    
     Ex-smoker    
     Light Smoker    
     Moderate smoker    
     Heavy Smoker    
Hoehn & Yahr    
     1.0    
     1.5    
     2.0    
     2.5    
     3.0    
Age in years at onset PD    
Mean (SD) [range]    
Median (IQR)    
     < 30    
     30 ≤ PD age < 40    
     40 ≤ PD age < 50    
     50 ≤ PD age < 60    
     60 ≤ PD age    
Disease duration    
Mean (SD) [range]    
Median (IQR) [range]    
Diabetes Status at 
screening 
   
     None    
     Type 1    
     Type 2    
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     Type 2a    
Total Cholesterol (mmol/L)    
Mean (SD) [range]    
Median (IQR)    
     ≤ 5 mmol/L    
     > 5 mmol/L    
QRISK® 2 
Mean (SD) 
   
     < 10%    
     ≥ 10%    
QRISK® 2    
Median (IQR) [range]    
     < 10%    
     ≥ 10%    
MoCA    
Mean (SD) [range]    
Median (IQR)     
MADRS    
Mean (SD) [range]    
Median (IQR)     
AST     
Mean (SD) [range]    
Median (IQR)     
ALT     
Mean (SD) [range]    
Median (IQR)     
CK    
Mean (SD) [range]    
Median (IQR)     
Table 7: Baseline and Demographic Data 
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 Mean (SD) 
Fully Adjusted* 
Adjusted Only for Baseline 
MDS-UPDRS Part III Score 
Coeff. Est. 
(80% CI) 
p-value 
Coeff. Est. 
(80% CI) 
p-value 
Primary analysis 
Placebo      
Simvastatin      
Sensitivity Analysis 
Placebo      
Simvastatin      
* The analysis is adjusted for baseline MDS-UPDRS part III, recruiting site, modified Hoehn & Yahr score, disease duration, 
gender and age at baseline. 
Table 8: Primary outcome analysis: linear regression of change in MDS-UPDRS score part III at 24 months in the OFF state. 
Secondary 
Outcomes 
State 
Fully Adjusted* (95% CI) 
Adjusted Only for Baseline 
Score (95% CI) 
24 months Repeated 24 months Repeated 
MDS-UPDRS      
Part II ON     
Total ON     
Timed Motor Tests      
Brain tap test OFF     
Walk test OFF     
Questionnaire      
MADRS ON     
ACE-III ON     
NMSS ON     
PDQ-39 ON     
KPPS ON     
Cholesterol      
Total NA     
HDL NA     
Total/HDL ratio NA     
Diabetes NA     
LED NA     
EMS - electromagnetic sensor; MADRS - Montgomery and Asberg Depression Rating Scale; ACE-III -The Addenbrooke’s 
Cognitive Assessment-III (ACE-III); NMSS - Non-Motor Symptom assessment scale (NMSS); PDQ-39 - Parkinson’s disease 
Questionnaire (PDQ-39); LED - levodopa-equivalent dose; KPPS - King’s PD pain scale; EQ-5D-5L - EuroQoL 5D-5L health 
status questionnaire. 
* Differences are adjusted for outcome measure at baseline (where available), recruiting site and modified Hoehn & Yahr score, 
disease duration, gender and age at baseline. 
Table 9: Differences between placebo and intervention group (i.e. placebo – intervention) with corresponding 95% confidence 
intervals for all secondary outcomes.  
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C. SUPERIORITY ANALYSIS CORRESPONDENCE 
 
From: Siobhan Creanor <siobhan.creanor@plymouth.ac.uk>  
Sent: Wednesday, September 18, 2019 1:41 PM 
To: bruce.levin@columbia.edu 
Subject: Futility studies 
 
Dear Professor Levin 
I’m emailing for some thoughts/advice regarding a current parallel group “futility/non-superiority” 
RCT that we are running in the UK.  The trial, PD STAT (http://www.isrctn.com/ISRCTN16108482) is 
managed by the Peninsula Clinical Trials Unit, and is one of the early Linked Clinical Trials in The Cure 
Parkinson’s Trust. 
The trial is still in follow-up and we are currently finalising the statistical analysis plan for 
independent review by the trial oversight committees (in the UK, things are run a little differently to 
the US).  I should add at this point, the trial team, including the statisticians, has not seen any data. 
As a futility/non-superiority study, we are very clear on the null hypotheses, etc.  However, 
throughout this trial I’ve been reflecting on some of the similarities/challenges with non-inferiority 
trials.  One point that we are particularly thinking about is the following. 
PD STAT was powered on a one-sided hypothesis, with one-sided alpha of 10% and 80% power 
(beta=20%).  We have a pre-specified margin on non-superiority of 3 points.   
Take a non-inferiority trial, with a one-sided primary hypothesis and say one-sided alpha of 5% and a 
pre-specified margin of non-inferiority, say again of 3 points.  However, despite the one-sided 
hypothesis, the recommended approach (by the European Medicines Agency, EMA) for analysis of 
non-inferiority trials is to calculate the TWO-SIDED confidence interval – so for this example would 
be the two-sided 90% confidence interval.  To ‘test’ the non-inferiority hypothesis, we look at 
whether this confidence interval lies completely on one side of the non-inferiority margin.  And 
importantly, if non-inferiority can be declared, it is then possible to assess for superiority using the 
same two-sided confidence interval.  From EMA 
(https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-
between-superiority-non-inferiority_en.pdf) “If the 95% confidence interval for the treatment effect 
not only lies entirely above -∆ but also above zero then there is evidence of superiority in terms of 
statistical significance at the 5% level (p<0.05).  See Figure 4.  In this case it is acceptable to calculate 
the p-value associated with a test of superiority and to evaluate whether this is sufficiently small to 
reject convincingly the hypothesis of no difference.  There is no multiplicity argument that affects this 
interpretation because, in statistical terms, it corresponds to a simple closed test procedure. Usually 
this demonstration of a benefit is sufficient on its own, provided the safety profiles of the new agent 
and the comparator are similar.” 
This makes me wonder if it would be appropriate/sensible to think of allowing for a similar pre-
specified approach in PD STAT – i.e. firstly assess for futility and then, if the results indicate promise 
of efficacy, assess for “superiority”.   
I appreciate this is not how the trial was designed as such – and I suspect it is a “long shot” that PD 
STAT would show superiority.  However, we currently have higher participant retention than we 
might have anticipated and given the primary endpoint is at 24 months (this has been an expensive 
 
 
 
 
 
PD STAT SAP V2.1 24082020 Page 47 of 48 
 
 
futility trial!), I think it’s important to consider in advance that we ‘may’ have evidence to support 
superiority, in addition to non-futility. 
Have you ever considered such an approach?   
 
Kind regards 
Siobhan 
 
Professor of Medical Statistics & Clinical Trials 
Director of PenCTU 
Faculty of Medicine & Dentistry 
University of Plymouth 
Plymouth Science Park 
Davy Road 
Plymouth  
PL6 8BX 
 
From: Bruce Levin <bl6@columbia.edu>  
Sent: 19 September 2019 00:35 
To: Siobhan Creanor <siobhan.creanor@plymouth.ac.uk> 
Subject: RE: Futility studies 
 
Dear Professor Creanor, 
          Yes, I have considered such an approach and I’m happy to say it is valid, although for slightly 
simpler reasons than the one you quote from the EMEA.  Let me give you that simpler reason first, in 
the context of futility testing, and then explain why it’s a little different from the non-inferiority 
scenario. 
          Your futility (non-superiority) design tests one null hypothesis, let’s call it H0(1), namely, that 
the true treatment effect is greater than or equal to the pre-specified margin of superiority, call it 
>0.  You wish to test a second null hypothesis, call it H0(2), which states that the true treatment effect 
is less than or equal to 0 (assuming one-sided testing) or that the true treatment effect is exactly equal 
to 0 (assuming two-sided testing), such that if you reject H0(2) you can declare “superiority”.  Thinking 
about the parameter space of a possible true treatment effects, the two null hypotheses comprise 
disjoint subspaces.  In plain English, if H0(1) is true then H0(2) cannot be true and vice 
versa.  Therefore, one cannot possibly make more than one type I error under any true state of nature, 
because there can only ever be (at most) one true null hypothesis.  Therefore, the family-wise type I 
error rate is controlled at level alpha and there is no inflation of type I error.  Voilà! 
          In the case of a non-inferiority trial, the EMEA cites the closed testing principle because it is 
implicitly contemplating two overlapping null hypotheses, namely, H0(1): the true treatment effect is 
less than or equal to – , and H0(2): the true treatment effect is less than or equal to 0.  The closed test 
principle allows us to test both hypotheses with no inflation of type I error because in order to reject 
H0(2), by the closed test principle one must reject both H0(1) and H0(2), because the intersection of H0(1) 
and H0(2) in this case is just H0(1).  However, because of the structure of the hypothesis space, if one 
rejects H0(2) one automatically rejects H0(1) by an a fortiori argument (picture the critical 
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regions).  [This argument is for one-sided testing of H0(2); if one wanted to conduct a two-sided test, 
the above argument by disjointedness would suffice.]   
          At this point, please note the structure of what is being considered in non-inferiority testing: if 
one already rejects H0(1) and declares non-inferiority, one is then naturally interested in testing the 
“home-run” hypothesis H0(2), hoping actually to declare superiority. 
          Now let’s look in the mirror to see what this says about non-superiority testing.  The analog 
would be H0(1) as we originally defined it, that the true treatment effect is greater than or equal to  
and if one already rejects that, one might be interested in testing the “anti-home-run” hypothesis, 
namely, H0(2): the true treatment effect is actually worse than 0.  The closed test principle again allows 
you to do this without inflation of type I error, again, because in order to reject H0(2) you have to reject 
both H0(1) and H0(2), but if you reject H0(2) you must already reject H0(1).   
          But this was not the pair of hypotheses you were inquiring about!  So, yes, go ahead and pre-
specify the one-sided H0(2): true treatment effect is less than or equal to 0 and reject it if and only if the 
lower endpoint of your 100%×(1–2 ) confidence interval lies above 0.  If so, even if you reject the 
original null hypothesis H0(1) of superiority and declare “futility” (more precisely, non-superiority), 
you can still declare the treatment effect significantly better than 0.  Of course, by the logic of futility 
testing, that may be small consolation, because presumably the margin of superiority corresponds to 
the minimal worthwhile treatment effect, such that there would be a clinical lack of enthusiasm for 
proceeding with smaller effects, even if significantly different from 0. 
           
          Bruce 
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